A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects

NCT02562950 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: GLPG1837 500 mg
DRUG: Midazolam
DRUG: GLPG1837 1000 mg

Sponsor

Lakefront Biotherapeutics NV